About Iambic Therapeutics
Iambic Therapeutics is a company based in San Diego (United States) founded in 2019 by Fred Manby and Thomas Miller.. Iambic Therapeutics has raised $306.23 million across 4 funding rounds from investors including Nvidia, Nexus Venture Partners and Orbimed. The company has 50 employees as of December 31, 2022. Iambic Therapeutics offers products and services including AI Platform and High-Throughput Experimentation. Iambic Therapeutics operates in a competitive market with competitors including Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others.
- Headquarter San Diego, United States
- Employees 50 as on 31 Dec, 2022
- Founders Fred Manby, Thomas Miller
-
Sectors
HealthcareTechnology
-
Email
***********
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Iambic Therapeutics, Inc
-
Annual Revenue
-
Net Profit
-
EBITDA
-
Total Equity Funding
$306.23 M (USD)
in 4 rounds
-
Latest Funding Round
$100 M (USD), Series C
Nov 10, 2025
-
Investors
Nvidia
& 27 more
-
Employee Count
50
as on Dec 31, 2022
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Iambic Therapeutics
Iambic Therapeutics offers a comprehensive portfolio of products and services, including AI Platform and High-Throughput Experimentation. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
AI tool for designing and testing drug molecules
System for rapid molecular testing and data generation
Funding Insights of Iambic Therapeutics
Iambic Therapeutics has successfully raised a total of $306.23M across 4 strategic funding rounds. The most recent funding activity was a Series C round of $100 million completed in November 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 4
- Last Round Series C — $100.0M
-
First Round
First Round
(14 Jul 2021)
- Investors Count 28
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov, 2025 | Amount | Series C - Iambic Therapeutics | Valuation |
investors |
|
| Apr, 2024 | Amount | Series B - Iambic Therapeutics | Valuation | Mubadala Capital , Exor | |
| Oct, 2023 | Amount | Series B - Iambic Therapeutics | Valuation | Ascenta Capital , Abingworth |
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in Iambic Therapeutics
Iambic Therapeutics has secured backing from 28 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include Nvidia, Nexus Venture Partners and Orbimed. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Mubadala Capital is engaged in investment management services.
|
Founded Year | Domain | Location | |
|
Health tech startups are invested in by Illumina Ventures.
|
Founded Year | Domain | Location | |
|
Venture capital firm that partners with entrepreneurs for product-first companies.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by Iambic Therapeutics
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - Iambic Therapeutics
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Iambic Therapeutics Comparisons
Competitors of Iambic Therapeutics
Iambic Therapeutics operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, Jazz Pharmaceuticals, BeiGene, Advanced Accelerator Applications and Incyte, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Novel biopharmaceutical medicines are developed for unmet medical needs.
|
|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed.
|
|
| domain | founded_year | HQ Location |
Small molecules are developed for cancer and skin disease treatments.
|
|
| domain | founded_year | HQ Location |
Cancer therapies are developed using selective pathway inhibitors.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Iambic Therapeutics
Frequently Asked Questions about Iambic Therapeutics
When was Iambic Therapeutics founded?
Iambic Therapeutics was founded in 2019 and raised its 1st funding round 2 years after it was founded.
Where is Iambic Therapeutics located?
Iambic Therapeutics is headquartered in San Diego, United States. It is registered at San Diego, California, United States.
Who is the current CEO of Iambic Therapeutics?
Thomas Miller is the current CEO of Iambic Therapeutics. They have also founded this company.
Is Iambic Therapeutics a funded company?
Iambic Therapeutics is a funded company, having raised a total of $306.23M across 4 funding rounds to date. The company's 1st funding round was a Series B of $103.23M, raised on Jul 14, 2021.
How many employees does Iambic Therapeutics have?
As of Dec 31, 2022, the latest employee count at Iambic Therapeutics is 50.
What does Iambic Therapeutics do?
AI-driven drug discovery platform for the treatment of cancer. The company has an AI-driven discovery platform and has discovered two candidates known as IAM-H1, a highly selective and brain-penetrant inhibitor of HER2 and its oncogenic mutants, and IAM-C1, a potential first-in-class selective dual CDK24 inhibitor to address unmet needs in terms of therapeutic window and treatment resistance in cell-cycle-driven cancers.
Who are the top competitors of Iambic Therapeutics?
Iambic Therapeutics's top competitors include Moderna, Jazz Pharmaceuticals and Advanced Accelerator Applications.
What products or services does Iambic Therapeutics offer?
Iambic Therapeutics offers AI Platform and High-Throughput Experimentation.
Who are Iambic Therapeutics's investors?
Iambic Therapeutics has 28 investors. Key investors include Nvidia, Nexus Venture Partners, Orbimed, Exor, and Abingworth.